Diagnostig
Diagnostig Ltd is a Bangor University spin-out that produces fully synthetic mycolic acids and develops ELISA-based diagnostic assays for mycobacterial infections, selling research reagents and point-of-care diagnostic technology to laboratories, research institutions, and biotechnology companies.
- Company typePrivate
- Founded2015
- HeadquartersBangor, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Diagnostig does
Diagnostig Ltd is a privately-held UK company founded in 2015 as a spin-out from Bangor University, operating from M-SParc science park on Anglesey, Wales. The company focuses on point-of-care diagnostics for mycobacterial infections, built on proprietary technology for producing fully synthetic mycolic acids — compounds unique to mycobacteria that serve as potent and selective immune signaling agents. Its product portfolio spans research-grade synthetic mycolic acids and their sugar esters (trehalose mono- and di-mycolates, arabinose, glucose, and glycerol mycolates), ELISA-based diagnostic assays targeting pathogens such as M. tuberculosis, M. bovis, M. paratuberculosis, M. ulcerans, and M. abscessus, and prototype point-of-care diagnostic devices developed in a Class 2 biological containment laboratory co-located with its chemical synthesis facility.
The company monetizes through direct, quote-based sales of research-only materials to laboratories, research institutions, and biotechnology companies, and has signaled an intent to commercialize its intellectual property through licensing for non-research applications. With a five-person scientific team led by Managing Director Prof. Mark Baird, Chairman and IP Manager Dr. Malcolm Jones, and Chief Commercial Officer Dr. Don Cardy, the company differentiates on a 300+ publication track record and a patent estate of nine filings spanning compositions, methods, and kits for mycobacterial detection. There is no disclosed external funding, no named customer base, and no evidence of scaled commercial operations in the available data.
Diagnostig firmographics
Firmographics- Name
- Diagnostig
- Legal name
- Diagnostig Ltd
- Website
- https://diagnostig.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Diagnostig Ltd is a Bangor University spin-out that produces fully synthetic mycolic acids and develops ELISA-based diagnostic assays for mycobacterial infections, selling research reagents and point-of-care diagnostic technology to laboratories, research institutions, and biotechnology companies.
- Ownership category
- akta.pro rank
Diagnostig industry classification
Industry- Product category
- Mycobacterial Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)
- akta.pro secondary industry
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)
Keywords
Where Diagnostig is headquartered
LocationHeadquarters
- HQ city
- Bangor
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Diagnostig business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain
Revenue model
- Research Products Sales: Sale of fully synthetic mycolic acids and their sugar esters as research-only materials to laboratories and research institutions. Products available in various stereochemical configurations with and without sugars attached.
- IP Licensing: Commercial opportunities available through licensing of the company's IP for commercial applications beyond research use.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Research products sold as research-only materials with commercial licensing available |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Diagnostig product offering
Product offeringCore offering
Diagnostig manufactures and supplies fully synthetic mycolic acids and their sugar esters (trehalose, arabinose, glucose, glycerol mycolates and wax esters) as research-only reagents, and develops Mycobacteria ELISA assays and Point of Care diagnostic devices for detecting infections such as M. tuberculosis, M. bovis, M. paratuberculosis, M. ulcerans, and M. abscessus. The company also offers IP licensing for commercial applications in diagnostics, vaccine adjuvants, and therapeutic agent development, leveraging its combined chemical synthesis and Class 2 biological containment facilities at M-SParc, Anglesey.
Product overview
Diagnostig is a Point of Care diagnostics company offering a portfolio of research products and diagnostic solutions centered on synthetic mycolic acid technology. The company's core offerings include fully synthetic mycolic acids and their sugar esters (trehalose, arabinose, glucose, and glycerol mycolates) as research reagents, alongside Mycobacteria ELISA assays for diagnosing infections such as M. tuberculosis, M. bovis, and M. paratuberculosis, and Point of Care diagnostic devices. All products are powered by the company's unique synthetic mycolic acid antigen platform, which enables specific mycobacterial disease detection.
Differentiator
Problem solved
Functional benefit
Products and services
- Fully Synthetic Mycolic Acids
Companies that use Diagnostig
Customer profileSegments4 records
Ideal customer profiles2 records
Diagnostig technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Diagnostig partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Bangor UniversitycoreDiagnostig was established in 2015 as a Bangor University Spin Out company, based on leading edge technology. The company maintains its origins from the university and operates within the university's ecosystem of innovation.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Diagnostig competitors and assessment
Company assessmentBroad incumbents
- bioMérieux: bioMérieux offers a broad microbiology diagnostics portfolio including BacT/ALERT culture systems and BioBall mycobacterial controls. It is a broad incumbent competing in the same mycobacterial disease detection space, with overlapping clinical customers.
- Cepheid (Danaher): Cepheid's GeneXpert MTB/RIF is the dominant molecular TB diagnostic platform globally. Both companies target mycobacterial disease detection, though Cepheid operates at vastly greater scale with nucleic acid-based testing versus Diagnostig's lipid-antigen ELISA approach.
- Becton Dickinson: BD supplies MGIT mycobacterial culture systems and microbiology lab consumables used in TB diagnostics. As a broad incumbent in clinical microbiology, BD serves the same laboratories that could be customers for Diagnostig's diagnostic kits.
- Abbott Diagnostics: Abbott's m2000 system and ARCHITECT immunoassays include infectious disease diagnostics relevant to TB and related mycobacterial diseases, placing it as a broad incumbent in the same target customer base.
- QuidelOrtho: QuidelOrtho produces Sofia immunoassay platforms used in point-of-care infectious disease testing. Their PoC infectious disease focus and immunoassay chemistry make them a comparable incumbent in adjacent diagnostic categories.
Direct peers
- Oxford Immunotec: Oxford Immunotec's T-SPOT.TB is a leading immunodiagnostic for latent tuberculosis infection. Both companies employ immunology-based detection of mycobacterial responses, making Oxford Immunotec a direct functional peer in TB diagnostics.
- Lionex GmbH: Lionex develops and sells ELISA kits and rapid tests specifically for mycobacterial infections including TB and M. avium subspecies paratuberculosis, making it a closely comparable niche competitor to Diagnostig in mycobacteria ELISA diagnostics.
- Bruker (Hain Lifescience): Hain Lifescience (now part of Bruker) developed the FluoroType Mycobacteria and GenoType Mycobacterium CM/AS molecular assays — directly competing diagnostic kits for mycobacterial species identification, addressing the same clinical use cases as Diagnostig's ELISA pipeline.
Emerging players
- Statens Serum Institut (SSI Diagnostica): SSI produces the tuberculin PPD RT23 used globally for TB skin testing and develops mycobacterial research reagents. It is comparable as a specialist supplier of mycobacterial antigens and diagnostics, with overlapping research-product customers.
- Creative Diagnostics: Creative Diagnostics is a niche supplier of mycobacterial antigens, ELISA kits, and research reagents for TB and related diseases. It is comparable to Diagnostig's research-products business as a small specialty provider of mycobacteria-related immunological reagents.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights6 records
Customer concentration
Diagnostig social profiles
Digital presenceDiagnostig financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diagnostig leadership team
Management profileNumber of profiles
Profiles5 records
Diagnostig funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diagnostig M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diagnostig
What does Diagnostig do?
Diagnostig manufactures and supplies fully synthetic mycolic acids and their sugar esters (trehalose, arabinose, glucose, glycerol mycolates and wax esters) as research-only reagents, and develops Mycobacteria ELISA assays and Point of Care diagnostic devices for detecting infections such as M. tuberculosis, M. bovis, M. paratuberculosis, M. ulcerans, and M. abscessus. The company also offers IP licensing for commercial applications in diagnostics, vaccine adjuvants, and therapeutic agent development, leveraging its combined chemical synthesis and Class 2 biological containment facilities at M-SParc, Anglesey.
Is Diagnostig a public or private company?
Diagnostig is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Diagnostig founded?
Diagnostig was founded in 2015. It employs 1 to 10 people.
Where is Diagnostig based?
Diagnostig is headquartered in Bangor, Australia, in the Oceania region.
How does Diagnostig make money?
Two revenue lines are on record. Research Products Sales are the primary driver. The others are IP Licensing.
Who are Diagnostig's main competitors?
Broad incumbents on record are bioMérieux, Cepheid (Danaher), Becton Dickinson, Abbott Diagnostics and QuidelOrtho. Direct peers are Oxford Immunotec, Lionex GmbH and Bruker (Hain Lifescience). Emerging players are Statens Serum Institut (SSI Diagnostica) and Creative Diagnostics.
Does Diagnostig have an API?
No public API is recorded for Diagnostig.
What industry is Diagnostig in?
Diagnostig's product category is Mycobacterial Diagnostics. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325413 and its SIC code is 2835.